Fundraising Fox

Immunomic Therapeutics

Rockville, US · Delaware corporation · 2 known investors

immunomix.com ↗

Immunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.

BiotechMedical Devicesin /immunomic-therapeutics-inc-@immunomix

Founders & leadership

DK
Dong-Gun KimExecutive Officer, Director
WG
WILLIAM G. HEARLChief Executive Officer and Director
RP
RONALD P. THIBOUTOTDirector
WB
WILLIAM BARRY MCDONALDDirector
CE
C. ERIC WINZERChief Financial Officer and Director
MD
MICHAEL D. LACKDirector
YG
Yang Gon JinDirector
SP
Steve ParkDirector
KA
Ki-Hong AhnDirector
RA
Robert AhlgrenDirector
JW
James WishartDirector
MC
Matthew ChangDirector

Investors · 2

Keiretsu ForumSan Francisco · $250K – $2M
Life Sciences Greenhouse InvestmentsHarrisburg · $250K – $500K

Reported raises · per SEC filings

Form D private placements
▶$6.5MraisedJun 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Yang Gon JinDirector
  • Steve ParkDirector
  • Robert AhlgrenDirector
  • Dong-Gun KimExecutive Officer, Director
  • James WishartDirector
  • Ki-Hong AhnDirector
  • Matthew ChangDirector
Offering amount
$16M
Amount sold
$6.5M
First sale
May 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedApr 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James WishartDirector
  • Dong-Gun KimExecutive Officer, Director
  • C. ERIC WINZERExecutive Officer
  • Robert AhlgrenDirector
  • Steve ParkDirector
  • Ki-Hong AhnDirector
  • Matthew ChangDirector
  • Michael LackDirector
  • Ronald ThiboutotDirector
  • Yang Gon JinDirector
Offering amount
$20.9M
Amount sold
$3M
First sale
Jan 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$77.7MraisedJan 2021 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • WILLIAM G. HEARLExecutive Officer, Director
  • C. ERIC WINZERExecutive Officer, Director
  • MICHAEL D. LACKDirector
  • JAMES W. WISHARTDirector
  • ALEX S KIMDirector
  • YANG-GON JINDirector
  • HYUK JOO JEEDirector
  • ARLO MCGINNDirector
  • RONALD P. THIBOUTOTDirector
Offering amount
$77.7M
Amount sold
$77.7M
Sales commissions
$3.1M
First sale
Feb 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$314.5KraisedAug 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • MICHAEL D. LACKDirector
  • WILLIAM G. HEARLExecutive Officer, Director
  • WILLIAM BARRY MCDONALDDirector
  • C. ERIC WINZERExecutive Officer, Director
  • JAMES W. WISHARTDirector
  • RONALD P. THIBOUTOTDirector
Offering amount
$314.5K
Amount sold
$314.5K
First sale
Jul 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.6MraisedMar 2017 · 47 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • WILLIAM G. HEARLExecutive Officer, Director
  • JAMES W. WISHARTDirector
  • RONALD P. THIBOUTOTDirector
  • WILLIAM BARRY MCDONALDDirector
  • C. ERIC WINZERExecutive Officer, Director
  • MICHAEL D. LACKDirector
Offering amount
$10M
Amount sold
$4.6M
Minimum investment
$25K
First sale
Feb 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news